Interpace Diagnostics Announces US Patent Approval for Patent Application No. 11,118, 231 B2 Titled: microRNAs as Biomarkers for Distinguishing Benign from Malignant Thyroid Neoplasms Oct 21, 2021
Interpace Pharma Solutions Announces New Capability in Spatial Biology/Precision Oncology Services May 17, 2021
Interpace Biosciences to Explore Strategic Alternatives for Maximizing Shareholder Value Apr 22, 2021
Interpace Biosciences Announces New PLA Code and Medicare Reimbursement Increase for Proprietary Thyroid Assay, ThyGeNEXT® Apr 5, 2021
